Physician profile
David Calabrese
NPI 1437178217
$1,404.77
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $250 · 2021: $542.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $962.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.59 | 2019-2020 | |
| Lilly USA, LLC | $65.32 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.22 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $30.86 | 2019 | |
| Mannkind Corporation | $26.44 | 2019 | |
| Lifescan, INC. | $26.18 | 2019-2021 | |
| Corcept Therapeutics | $25.75 | 2020-2021 | |
| Pfizer INC. | $22.98 | 2019-2021 | |
| Valeritas, INC. | $19.48 | 2019 | |
| Vivus LLC | $15.00 | 2020 | |
| Aytu Biopharma, INC. | $14.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.88 | 2019 | |
| Merck Sharp & Dohme LLC | $13.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.75 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $11.88 | 2019 | |
| Dexcom, INC. | $11.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Calabrese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.